×
About 26,423 results

ALLMedicine™ Severe Acute Respiratory Syndrome Center

Research & Reviews  12,641 results

Surviving the Rookie Virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)...
https://doi.org/10.1177/0963689721993769
Cell Transplantation; Tsai SF, Lu KY et. al.

Apr 12th, 2021 - Until July 29th, the number of confirmed coronavirus (COVID-19) cases worldwide has risen to over 16 million, within which 655 k deaths. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) emerges as the 11th global pandemic disease, showi...

Safety and feasibility of transcatheter aortic valve replacement in COVID-19 patients: ...
https://doi.org/10.1016/j.carrev.2021.03.022
Cardiovascular Revascularization Medicine : Including Mol... Giacomin E, Barioli A et. al.

Apr 12th, 2021 - In 2020, the coronavirus disease 2019 (COVID-19) pandemic has led to a decrease in interventional treatment for structural heart disease worldwide. In this context, the management of patients with symptomatic severe aortic stenosis (AS) or biopros...

Enhanced Throughput of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)...
https://doi.org/10.1016/j.jviromet.2021.114149
Journal of Virological Methods; Lu X, Sakthivel SK et. al.

Apr 11th, 2021 - A multiplex real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was developed based on the same primer and probe sequences of an existing U.S. CDC ...

see more →

Guidelines  241 results

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
https://www.nejm.org/doi/full/10.1056/NEJMc2101927?query=recirc_mostViewed_railB_article
New England Journal of Medicine; Keehner J, Horton LE et. al.

Mar 22nd, 2021 - Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dos...

Post-acute COVID-19 syndrome
https://www.nature.com/articles/s41591-021-01283-z
Nature Medicine; Nalbandian, A. et. al.

Mar 21st, 2021 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patie...

2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874914
European Journal of Cancer (Oxford, England : 1990); Giesen N, Sprute R et. al.

Mar 6th, 2021 - The worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious coronavirus disease (COVID-19) has posed a unique challenge to medical staff, patients and their families. Patients with cancer,...

FDA Briefing Document: Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19
https://www.fda.gov/media/146217/download
Vaccines and Related Biological Products Advisory Committee Meeting

Feb 25th, 2021 - On February 4, 2021, Janssen Biotech, Inc. (the Sponsor) submitted an Emergency Use Authorization (EUA) request to FDA for an investigational vaccine intended to prevent COVID19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...

Oral manifestations of COVID-19: Brief review
https://pubmed.ncbi.nlm.nih.gov/33590976/
Dental and Medical Problems; Paradowska-Stolarz AM.

Feb 15th, 2021 - The infection with a new type of virus - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - called coronavirus disease 2019 (COVID-19) was first described in December 2019, in Wuhan, China. Due to the gastrointestinal mucosa tropism of...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  13,005 results

Surviving the Rookie Virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)...
https://doi.org/10.1177/0963689721993769
Cell Transplantation; Tsai SF, Lu KY et. al.

Apr 12th, 2021 - Until July 29th, the number of confirmed coronavirus (COVID-19) cases worldwide has risen to over 16 million, within which 655 k deaths. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) emerges as the 11th global pandemic disease, showi...

Safety and feasibility of transcatheter aortic valve replacement in COVID-19 patients: ...
https://doi.org/10.1016/j.carrev.2021.03.022
Cardiovascular Revascularization Medicine : Including Mol... Giacomin E, Barioli A et. al.

Apr 12th, 2021 - In 2020, the coronavirus disease 2019 (COVID-19) pandemic has led to a decrease in interventional treatment for structural heart disease worldwide. In this context, the management of patients with symptomatic severe aortic stenosis (AS) or biopros...

Enhanced Throughput of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)...
https://doi.org/10.1016/j.jviromet.2021.114149
Journal of Virological Methods; Lu X, Sakthivel SK et. al.

Apr 11th, 2021 - A multiplex real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was developed based on the same primer and probe sequences of an existing U.S. CDC ...

see more →

News  527 results

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
https://www.nejm.org/doi/full/10.1056/NEJMc2101927?query=recirc_mostViewed_railB_article
New England Journal of Medicine; Keehner J, Horton LE et. al.

Mar 22nd, 2021 - Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dos...

Post-acute COVID-19 syndrome
https://www.nature.com/articles/s41591-021-01283-z
Nature Medicine; Nalbandian, A. et. al.

Mar 21st, 2021 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patie...

FDA Briefing Document: Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19
https://www.fda.gov/media/146217/download
Vaccines and Related Biological Products Advisory Committee Meeting

Feb 25th, 2021 - On February 4, 2021, Janssen Biotech, Inc. (the Sponsor) submitted an Emergency Use Authorization (EUA) request to FDA for an investigational vaccine intended to prevent COVID19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...

Oral manifestations of COVID-19: Brief review
https://pubmed.ncbi.nlm.nih.gov/33590976/
Dental and Medical Problems; Paradowska-Stolarz AM.

Feb 15th, 2021 - The infection with a new type of virus - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - called coronavirus disease 2019 (COVID-19) was first described in December 2019, in Wuhan, China. Due to the gastrointestinal mucosa tropism of...

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
https://science.sciencemag.org/content/371/6529/eabf4063
Science Dan JM, Mateus J et. al.

Feb 4th, 2021 - Immune memory against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) helps to determine protection against reinfection, disease risk, and vaccine efficacy. Using 188 human cases across the range of severity of COVID-19, Dan et al.

see more →

Patient Education  7 results see all →